Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

GlaxoSmithKline Adopts Multi-Faceted Strategy for China

publication date: Mar 5, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
GlaxoSmithKline is willing to explore all paths to increase its China presence. CEO Andrew Witty said the company is looking at a range of strategies in China, including acquisitions, more SFDA drug approvals, building its R&D effort, and adding personnel to its already large 4,000 member sales force. Even though China’s government is reducing prices on drugs, China’s market – already big and growing quickly – is too attractive a target for GSK to ignore. More details....

Stock Symbol: (NYSE: GSK)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners